Herpes simplex virus drug resistance-HSV thymidine kinase mutants

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The widespread use of nucleoside analog antivirals to treat patients infected with herpes simplex virus (HSV) is indicted by the statement in a recent publication that, “More than 2.3 million kg of these drugs have been prescribed…in >30 countries” (1). Many clinical trials have demonstrated the effectiveness of these antivirals. However, clinical studies have also reported the detection of drugresistant viral mutants, particularly important in the care of immunosuppressed patients. Laboratory studies have indicated the mechanisms of viral resistance. The development of drug-resistant mutants of HSV has raised the issue of the potential pathogenicity of these mutants, and also mechanisms of HSV infection whereby such mutants may arise.

Original languageEnglish (US)
Title of host publicationEmerging Neurological Infections
PublisherCRC Press
Pages397-414
Number of pages18
ISBN (Electronic)9780849340871
ISBN (Print)9780824754235
StatePublished - Jan 1 2005

Fingerprint

Thymidine Kinase
Simplexvirus
Drug Resistance
Antiviral Agents
Virus Diseases
Nucleosides
Pharmaceutical Preparations
Virulence
Patient Care
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Tenser, R. (2005). Herpes simplex virus drug resistance-HSV thymidine kinase mutants. In Emerging Neurological Infections (pp. 397-414). CRC Press.
Tenser, Richard. / Herpes simplex virus drug resistance-HSV thymidine kinase mutants. Emerging Neurological Infections. CRC Press, 2005. pp. 397-414
@inbook{e2cf9da9280743799173be31ce56d1bd,
title = "Herpes simplex virus drug resistance-HSV thymidine kinase mutants",
abstract = "The widespread use of nucleoside analog antivirals to treat patients infected with herpes simplex virus (HSV) is indicted by the statement in a recent publication that, “More than 2.3 million kg of these drugs have been prescribed…in >30 countries” (1). Many clinical trials have demonstrated the effectiveness of these antivirals. However, clinical studies have also reported the detection of drugresistant viral mutants, particularly important in the care of immunosuppressed patients. Laboratory studies have indicated the mechanisms of viral resistance. The development of drug-resistant mutants of HSV has raised the issue of the potential pathogenicity of these mutants, and also mechanisms of HSV infection whereby such mutants may arise.",
author = "Richard Tenser",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780824754235",
pages = "397--414",
booktitle = "Emerging Neurological Infections",
publisher = "CRC Press",

}

Tenser, R 2005, Herpes simplex virus drug resistance-HSV thymidine kinase mutants. in Emerging Neurological Infections. CRC Press, pp. 397-414.

Herpes simplex virus drug resistance-HSV thymidine kinase mutants. / Tenser, Richard.

Emerging Neurological Infections. CRC Press, 2005. p. 397-414.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Herpes simplex virus drug resistance-HSV thymidine kinase mutants

AU - Tenser, Richard

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The widespread use of nucleoside analog antivirals to treat patients infected with herpes simplex virus (HSV) is indicted by the statement in a recent publication that, “More than 2.3 million kg of these drugs have been prescribed…in >30 countries” (1). Many clinical trials have demonstrated the effectiveness of these antivirals. However, clinical studies have also reported the detection of drugresistant viral mutants, particularly important in the care of immunosuppressed patients. Laboratory studies have indicated the mechanisms of viral resistance. The development of drug-resistant mutants of HSV has raised the issue of the potential pathogenicity of these mutants, and also mechanisms of HSV infection whereby such mutants may arise.

AB - The widespread use of nucleoside analog antivirals to treat patients infected with herpes simplex virus (HSV) is indicted by the statement in a recent publication that, “More than 2.3 million kg of these drugs have been prescribed…in >30 countries” (1). Many clinical trials have demonstrated the effectiveness of these antivirals. However, clinical studies have also reported the detection of drugresistant viral mutants, particularly important in the care of immunosuppressed patients. Laboratory studies have indicated the mechanisms of viral resistance. The development of drug-resistant mutants of HSV has raised the issue of the potential pathogenicity of these mutants, and also mechanisms of HSV infection whereby such mutants may arise.

UR - http://www.scopus.com/inward/record.url?scp=84883962426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883962426&partnerID=8YFLogxK

M3 - Chapter

SN - 9780824754235

SP - 397

EP - 414

BT - Emerging Neurological Infections

PB - CRC Press

ER -

Tenser R. Herpes simplex virus drug resistance-HSV thymidine kinase mutants. In Emerging Neurological Infections. CRC Press. 2005. p. 397-414